Meta-analysis of Victoza (liraglutide) trials demonstrates efficacy in type 2 diabetes- Novo Nordisk

New findings from a network meta-analysis show that treatment with Victoza (liraglutide), from Novo Nordisk, provides a greater HbA1c reduction and an improved likelihood of reaching glycaemic goals compared to SGLT-2 inhibitors in people with type 2 diabetes who are inadequately controlled with metformin alone or in combination with sulfonylurea, DPP-4 inhibitors or thiazolidinedione. The meta-analysis evaluated the relative efficacy of liraglutide to SGLT-2 inhibitors, including canagliflozin, empagliflozin and dapagliflozin.

In an analysis of 17 randomised controlled trials, liraglutide demonstrated greater reductions in mean HbA1c compared to all SGLT-2 inhibitors (placebo-adjusted mean change -1.01%/-1.18% for liraglutide 1.2 mg/1.8 mg; -0.64%/-0.79% for canagliflozin 100 mg/300 mg; -0.32%/-0.38% for dapagliflozin 5 mg/10 mg; -0.59%/-0.62% for empagliflozin 10 mg/25 mg). Findings were presented at the World Diabetes Congress of the International Diabetes Federation.